Literature DB >> 20382351

Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey.

Eric L Vey1, Inna Kovelman.   

Abstract

Duloxetine, a dual acting norepinephrine serotonin reuptake inhibitor, is a relatively new pharmacologic agent utilized in the treatment of depression, as well as diabetic neuropathic pain, fibromyalgia, and female stress urinary incontinence. This expanding scope of usage will inevitably lead to its eventual appearance during routine post-mortem toxicologic assays. Currently there is a paucity of post-mortem toxicologic data concerning duloxetine. The current report provides six additional case reports of post-mortem duloxetine levels, along with a review of duloxetine's pharmacokinetics, and the toxicologic manifestations which have been reported in the literature. The post-mortem levels reported, including the highest level recorded to date, are integrated with previously published reports to generate a foundation for a nascent guide to the interpretation of post-mortem duloxetine levels that could be encountered during routine post-mortem toxicologic analyses, and establish a basis upon which the establishment of toxic and lethal thresholds for this compound can be further elucidated with greater clarity. Copyright (c) 2010 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382351     DOI: 10.1016/j.jflm.2010.02.002

Source DB:  PubMed          Journal:  J Forensic Leg Med        ISSN: 1752-928X            Impact factor:   1.614


  2 in total

1.  Determination of Patient Adherence for Duloxetine in Urine.

Authors:  Haley A Mulder; Greg L McIntire; Frank N Wallace; Justin L Poklis
Journal:  J Anal Toxicol       Date:  2022-10-14       Impact factor: 3.220

2.  Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.